11.15 -0.26 (-2.28%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 17.3 | 1-year : | 20.34 |
Resists | First : | 14.81 | Second : | 17.41 |
Pivot price | 11.95 | |||
Supports | First : | 10.6 | Second : | 8.81 |
MAs | MA(5) : | 11.44 | MA(20) : | 12.74 |
MA(100) : | 12.72 | MA(250) : | 8.82 | |
MACD | MACD : | -1 | Signal : | -0.9 |
%K %D | K(14,3) : | 9.5 | D(3) : | 11.6 |
RSI | RSI(14): 37.4 | |||
52-week | High : | 17.42 | Low : | 3.93 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALXO ] has closed above bottom band by 31.3%. Bollinger Bands are 6.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 11.48 - 11.55 | 11.55 - 11.6 |
Low: | 10.41 - 10.5 | 10.5 - 10.57 |
Close: | 11.02 - 11.15 | 11.15 - 11.26 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Wed, 27 Mar 2024
ALX Oncology (NASDAQ:ALXO) Shares Gap Up to $11.19 - MarketBeat
Sun, 24 Mar 2024
ALX Oncology (NASDAQ:ALXO) Shares Gap Down to $12.51 - Defense World
Sun, 24 Mar 2024
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sat, 23 Mar 2024
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Tue, 12 Mar 2024
Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way? - Simply Wall St
Fri, 08 Mar 2024
Stifel downgrades ALX Oncology to hold, sees evorpacept as fully valued (NASDAQ:ALXO) - Seeking Alpha
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 50 (M) |
Shares Float | 22 (M) |
Held by Insiders | 2.7 (%) |
Held by Institutions | 97.6 (%) |
Shares Short | 3,480 (K) |
Shares Short P.Month | 3,620 (K) |
EPS | -3.75 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 3.79 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -38.8 % |
Return on Equity (ttm) | -71 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -3.38 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -130 (M) |
Levered Free Cash Flow | -76 (M) |
PE Ratio | -2.99 |
PEG Ratio | 0 |
Price to Book value | 2.93 |
Price to Sales | 0 |
Price to Cash Flow | -4.29 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |